CRAX2MACE模型的外部验证
该研究对用于估计疑似冠心病患者2年主要不良心血管事件(MACE)风险的CRAX2MACE评分进行外部验证,纳入2,985例行临床指征SPECT心肌灌注显像且有MACE随访数据的患者。CRAX2MACE预测2年MACE的AUC为0.710,显著高于负荷总灌注缺损(AUC 0.669,P=0.010)和缺血总灌注缺损(AUC 0.664,P<0.001),模型拟合良好且校准良好(Brier评分0.071)。
要点
- CRAX2MACE预测2年MACE的AUC为0.710,高于负荷总灌注缺损的0.669和缺血总灌注缺损的0.664。
- 2年内243例(8.1%)患者发生MACE(血运重建、心肌梗死或死亡)。
- 模型拟合良好(P=0.103)且校准良好,Brier评分为0.071。
核心结论
- 在外部人群中,CRAX2MACE对2年MACE的预测性能高于定量灌注指标。
- 该模型使用简单,可实施以辅助医生评估患者风险。
研究设计与样本
- 对CRAX2MACE评分进行外部验证,纳入2,985例行临床指征SPECT且有MACE随访数据的患者。
- 比较CRAX2MACE与负荷总灌注缺损及缺血总灌注缺损预测2年内MACE(血运重建、心肌梗死或死亡)的性能,使用受试者工作特征曲线下面积(AUC)。
- 采用校准图、Brier评分和Hosmer-Lemeshow检验评估校准度。
主要发现
- 2年内243例(8.1%)患者发生MACE。
- CRAX2MACE的AUC为0.710(95%CI 0.677-0.743),显著高于负荷总灌注缺损(AUC 0.669,95%CI 0.632-0.706,P=0.010)。
- CRAX2MACE的AUC显著高于缺血总灌注缺损(AUC 0.664,95%CI 0.627-0.700,P<0.001)。
- 模型拟合良好(P=0.103),校准良好,Brier评分为0.071。
临床怎么用
- 原文结论指出该模型使用简单,可实施以辅助医生评估患者风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Single-photon emission computed tomography (SPECT) myocardial perfusion is frequently used to predict risk of major adverse cardiovascular events (MACE). We performed an external validation of the CRAX2MACE score, developed to estimate 2-year risk of MACE in patients with suspected coronary artery disease (CAD). METHODS: Patients who underwent clinically indicated SPECT with available follow-up for MACE were included (N = 2,985). The prediction performance for MACE (revascularization, myocardial infarction, or death) within 2 years for CRAX2MACE was compared with stress and ischemic total perfusion deficit (TPD) using area under the receiver operating characteristic curve (AUC). Calibration was assessed with calibration plots, Brier score, and the Hosmer-Lemeshow test. RESULTS: MACE occurred within 2 years in 243 (8.1%) patients. The AUC for CRAX2MACE (0.710, 95% CI 0.677-0.743) was significantly higher compared to stress TPD (AUC 0.669, 95% CI 0.632-0.706, P = .010) and ischemic TPD (AUC 0.664, 95% CI 0.627-0.700, P < .001). The model had acceptable goodness-of-fit (P = .103) and was well-calibrated with Brier score of 0.071. CONCLUSION: CRAX2MACE had higher predictive performance for 2-year MACE than quantitative perfusion in an external population. The current model is simple to use and could be implemented to assist physicians when estimating patient risk.
引用
- Hijazi W, Leslie W, Filipchuk N, et al. External validation of the CRAX2MACE model. J Nucl Cardiol. 2022. PMID: 35419699. doi:10.1007/s12350-022-02964-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。